Exodus Point Capital Management, LP Surface Oncology, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$1.42 - $3.15 $27,468 - $60,933	-19,344 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.65 - $5.08 $24,054 - $46,111	9,077 Added 88.41%	19,344 $57,000
Q4 2021 Feb 11, 2022	SELL	$4.73 - $7.9 $17,392 - $29,048	-3,677 Reduced 26.37%	10,267 $49,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $7.98 $95,976 - $148,428	-18,600 Reduced 57.15%	13,944 $106,000
Q2 2021 Aug 16, 2021	SELL	$6.45 - $9.09 $502,803 - $708,601	-77,954 Reduced 70.55%	32,544 $243,000

Q1 2021 May 17, 2021	BUY	$7.25 - $13.82 $642,284 - $1.22 Million	88,591 Added 404.4%	110,498 $862,000
Q4 2020 Feb 16, 2021	BUY	$6.87 - $10.48 $150,501 - $229,585	21,907 New	21,907 $202,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.